The estimated Net Worth of Kathryn Romano is at least $9.19 Milione dollars as of 28 February 2024. Ms Romano owns over 10,000 units of Krystal Biotech Inc stock worth over $3,565,497 and over the last 5 years she sold KRYS stock worth over $5,428,285. In addition, she makes $200,871 as Chief Accounting Officer at Krystal Biotech Inc.
Sign up
Ms Romano KRYS stock SEC Form 4 insiders trading
Ms has made over 5 trades of the Krystal Biotech Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she exercised 10,000 units of KRYS stock worth $317,800 on 28 February 2024.
The largest trade she's ever made was selling 53,428 units of Krystal Biotech Inc stock on 19 May 2023 worth over $5,428,285. On average, Ms trades about 9,270 units every 32 days since 2020. As of 28 February 2024 she still owns at least 17,936 units of Krystal Biotech Inc stock.
You can see the complete history of Ms Romano stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Kathryn A. Romano biography
Kathryn A. Romano is the Chief Accounting Officer at Krystal Biotech Inc.
What is the salary of Ms Romano?
As the Chief Accounting Officer of Krystal Biotech Inc, the total compensation of Ms Romano at Krystal Biotech Inc is $200,871. There are 7 executives at Krystal Biotech Inc getting paid more, with Krish S. Krishnan M.B.A., M.S. having the highest compensation of $1,008,932.
How old is Ms Romano?
Ms Romano is 40, she's been the Chief Accounting Officer of Krystal Biotech Inc since . There are 12 older and 1 younger executives at Krystal Biotech Inc. The oldest executive at Krystal Biotech Inc is Dr. Jing L. Marantz M.B.A., M.D., Ph.D., 56, who is the Chief Bus. Officer.
What's Ms Romano's mailing address?
Kathryn's mailing address filed with the SEC is C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203.
Insiders trading at Krystal Biotech Inc
Over the last 7 years, insiders at Krystal Biotech Inc have traded over $166,816,526 worth of Krystal Biotech Inc stock and bought 536,800 units worth $5,949,380 . The most active insiders traders include Daniel Janney, Dino A Rossi e Krish S Krishnan. On average, Krystal Biotech Inc executives and independent directors trade stock every 40 days with the average trade being worth of $8,043,043. The most recent stock trade was executed by Suma Krishnan on 11 June 2024, trading 50,000 units of KRYS stock currently worth $8,788,000.
What does Krystal Biotech Inc do?
krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)
What does Krystal Biotech Inc's logo look like?
Complete history of Ms Romano stock trades at Krystal Biotech Inc
Krystal Biotech Inc executives and stock owners
Krystal Biotech Inc executives and other stock owners filed with the SEC include:
-
Krish S. Krishnan M.B.A., M.S.,
Founder, Chairman, Pres & CEO -
Krish S. Krishnan,
Chairman, Pres & CEO -
Dr. Andreas C. Orth,
Exec. VP & Chief Commercial Officer -
Suma M. Krishnan,
Founder, COO & Director -
Krish Krishnan,
Chairman of the Board, President, Chief Executive Officer -
Suma Krishnan,
Founder, Chief Operating Officer, Director -
Pooja Agarwal,
Senior Vice President, Product Development -
Kathryn A. Romano,
Chief Accounting Officer -
R. Douglas Norby,
Lead Independent Director -
Dino Rossi,
Independent Director -
Daniel Janney,
Independent Director -
Julian Gangolli.,
Independent Director -
Ashley Robinson,
IR Contact Officer -
Kirti Ganorkar,
Independent Director -
J. Christopher Naftzger,
Chief Legal Officer, Corporate Secretary -
Jennifer Chien,
Chief Commercial Officer -
Kathryn Romano,
Chief Accounting Officer -
David Glynn,
Gen. Counsel, Commercial & Compliance -
Meg Dodge,
VP of Investor Relations & Corp. Communications -
Dr. Jing L. Marantz M.B.A., M.D., Ph.D.,
Chief Bus. Officer -
Pooja Agarwal,
Sr. VP of Product Devel. -
Whitney Glad Ijem,
Sr. VP of Strategy & Bus. Devel. -
Josh Suskin,
Director of HR & Operations -
Katherine Tuminello,
HR & Office Mang. -
John Karakkal,
VP of North American Sales and Marketing -
Gloria Lin,
Accounting Mang. -
Catherine Mazzacco,
Director -
Krish S Krishnan,
President and CEO -
Antony A Riley,
Chief Financial Officer -
Jennifer Kayden Lee,
Chief Commercial Officer -
Christopher Mason,
Director -
Jing L. Marantz,
Chief Business Officer -
Everett Rand Sutherland,
Director